Advertisement

Ovarian Cancer

Prognostic Role of CD1a in OV and Recurrent OV Outcomes

Nov 20, 2024

The following is a summary of “CD1a affects the recurrence and prognosis of ovarian cancer,” published in the November 2024 issue of Obstetrics and Gynecology by Zhu et al.    Ovarian ca...

Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer.

Nov 04, 2024

In epithelial ovarian cancer (EOC), platinum resistance, potentially mediated by cancer stem cells (CSCs), often leads to relapse and treatment failure. Here, the role of spindle pole body component 2...

Prognostic impact of microscopic residual disease after neoadjuvant chemotherapy in patients undergoing interval debulking surgery for advanced ovarian cancer.

Oct 14, 2024

To determine the prognostic impact of microscopic residual disease after neoadjuvant chemotherapy (NACT) in patients undergoing interval debulking surgery (IDS) for advanced epithelial ovarian cancer ...

SHCBP1 promotes cisplatin resistance of ovarian cancer through AKT/mTOR/Autophagy pathway.

Oct 14, 2024

Ovarian cancer caused the highest cancer-related mortality among female reproductive system malignancies. Platinum-based chemotherapy is still the footstone of the chemotherapy for ovarian cancer. How...

Exposure-response relationships of mirvetuximab soravtansine in patients with folate receptor-α-positive ovarian cancer: Justification of therapeutic dose regimen.

Sep 23, 2024

This study aimed to investigate exposure-response (ER) relationships in efficacy and safety for mirvetuximab soravtansine (MIRV) which is a first-in-class antibody-drug conjugate approved for the trea...

Complex Expression Patterns of HDAC6 and ARID1A in Endometriosis Subtypes

Sep 20, 2024

The following is a summary of “Expression patterns of HDAC6 in correlation to ARID1A status in different subtypes of endometriosis: A retrospective tissue microarray analysis,” published in the Au...

Patient-derived acellular ascites fluid affects drug responses in ovarian cancer cell lines through the activation of key signalling pathways.

Sep 09, 2024

Malignant ascites is commonly produced in advanced epithelial ovarian cancer (EOC) and serves as unique microenvironment for tumour cells. Acellular ascites fluid (AAF) is rich in signalling molecules...

MRG Prognostic Signature May Predict Survival Time of Patients With Ovarian Cancer

Aug 05, 2024

Ovarian cancer is a female-specific malignancy with high morbidity and mortality. The metabolic reprogramming of tumor cells is closely related to the biological behavior of tumors. The prognostic ...

Circular RNA circ_ARHGEF28 inhibits MST1/2 dimerization to suppress Hippo pathway to induce cisplatin resistance in ovarian cancer.

Jul 22, 2024

Cisplatin is integral to ovarian cancer treatment, yet resistance to this drug often results in adverse patient outcomes. The association of circular RNA (circRNA) with cisplatin resistance in ovarian...

Women With Endometriosis at Increased Risk for Ovarian Cancer

Jul 19, 2024

Women with endometriosis have an increased risk of ovarian cancer, with the highest risk seen for women with deep infiltrating endometriosis and/or ovarian endometriomas, according to a study publishe...

Prophylactic mesh to prevent incisional hernia in laparotomy for ovarian tumors.

Jun 24, 2024

Incisional hernias are a common complication of midline laparotomies. The aim of this study was to determine the impact of prophylactic mesh placement after midline laparotomy for ovarian tumors on th...

Batiraxcept-Paclitaxel Combination Shows Promise in High AXL-Expressing, Platinum-Resistant Ovarian Cancer

Jun 06, 2024

Results from the Phase 3 AXLerate-OC trial showed that the combination of batiraxcept and paclitaxel demonstrated a statistically significant improvement in progression-free survival (PFS) and overall...

Recent Insights into the Roles of PEST-Containing Nuclear Protein.

May 20, 2024

PEST-containing nuclear protein (PCNP), a short-lived small nuclear protein with 178 amino acids, is a nuclear protein containing two PEST sequences. PCNP is highly expressed in several malignant tumo...

miR-3653-3p Expression in PBMCs: Unveiling the Diagnostic Potential for Ovarian Cancer.

May 06, 2024

Ovarian cancer is typically diagnosed at an advanced stage, recurs early and often, and currently lacks effective treatment. Therefore, overall survival and progression-free survival are relatively sh...

Long non-coding RNA RAD51-AS1 promotes the tumorigenesis of ovarian cancer by elevating EIF5A2 expression.

Apr 08, 2024

The present study aims to determine the molecular mechanism mediated by RAD51 antisense RNA 1 (RAD51-AS1) in ovarian cancer (OvCA).The data associated with RAD51-AS1 in OvCA were obtained from the Can...

Relationships of SIGLEC family-related lncRNAs with clinical prognosis and tumor immune microenvironment in ovarian cancer.

Apr 01, 2024

Long non-coding RNAs (lncRNAs) and Sialic acid-binding immunoglobulin-type lectin (SIGLEC) family members play an important role in proliferation, apoptosis, immune-cell activation and tumor developme...

Management of retroperitoneal high-grade serous carcinoma of unknown origin: A case report.

Mar 11, 2024

Retroperitoneal high-grade serous carcinoma (HGSC) of unknown origin is a sporadic tumor that can originate from ovarian cancer. Herein, we report the case of a woman with retroperitoneal HGSC of unkn...

Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i) Associated Diabetic Ketoacidosis in Oncology Patients: A Case Series and Literature Review.

Mar 11, 2024

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) use is associated with an increased risk of diabetic ketoacidosis (DKA). The clinical data regarding the use of SGLT2i and its potential side effects...

Young Women's Perspectives on Being Screened for Hereditary Breast and Ovarian Cancer Risk During Routine Primary Care.

Mar 07, 2024

The U.S. Preventive Services Task Force recommends screening women to identify individuals eligible for genetic counseling based on a priori hereditary breast and ovarian cancer (HBOC) risk (i.e., ris...

Contrast-enhanced CT radiomics for preoperative prediction of stage in epithelial ovarian cancer: a multicenter study.

Mar 07, 2024

Preoperative prediction of International Federation of Gynecology and Obstetrics (FIGO) stage in patients with epithelial ovarian cancer (EOC) is crucial for determining appropriate treatment strategy...

SUBSPECIALTIES

Advertisement